The ascendancy of Viagra and its influence on the medicinal landscape presents a complicated question for shareholders. While the initial sales data were astounding, the intellectual property has ended, leading to a wave of generic alternatives that are chipping away at earnings. Furthermore, the market is facing challenges related to demographi… Read More